Amylyx Pharmaceuticals Inc AI Stock Analysis
Want to see AMLX full AI Analyst Report?
Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis
Amylyx Pharmaceuticals Inc
(NASDAQ:AMLX)
The score is held down primarily by deteriorated financial performance (revenue collapsing to $0, multi-year losses, and significant cash burn), partially offset by a strong balance sheet and a highly positive earnings call centered on Phase III success and an on-track NDA timeline. Technicals are neutral and valuation is constrained by negative earnings.
Amylyx Pharmaceuticals Inc (AMLX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.42B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.67M
- Price to Earnings (P/E)
- -18.7
- Beta (1Y)
- 0.93
- Revenue Growth
- ―
- EPS Growth
- 19.61%
- Country
- US
- Employees
- 136
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Amylyx Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipelin...
How the Company Makes Money
As of the latest available public information, Amylyx’s revenue model is primarily tied to the commercialization of its lead product and, secondarily, to potential collaboration-related income. Product revenue: Amylyx previously generated sales from...
Amylyx Pharmaceuticals Inc Earnings Call Summary
The call was strongly positive, driven by statistically significant and clinically meaningful phase III LUCIDITY results, a planned NDA submission by year-end, substantial funding, and progress toward a potential 2027 launch. The company also reported positive pipeline and commercial developments. The main negatives were higher operating expenses and the early stage of payer, pricing, label, expanded-access, and certain pipeline discussions.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management remains on track to submit the avexitide NDA to the FDA by the end of this year, with a potential approval and launch in 2027; it is targeting a 2027 IND filing for AMX0318, expects payer information exchanges to begin in the first quarter of the year, and expects a good concentration up front for launch that will build over time as educational efforts expand. The company estimates approximately 160,000 people living with PBH in the U.S., including approximately 118,000 people estimated to have received Roux-en-Y gastric bypass surgery and approximately 48,000 people estimated to have received sleeve gastrectomy; it also said its estimates are that about 120,000 of the 160,000 currently had Roux-en-Y gastric bypass. Management said it will not give interim EAP numbers, it is too early to discuss persistency rates, and it is little bit early to discuss the specifics on pricing.
Amylyx Pharmaceuticals Inc Financial Statement Overview
Summary
Operating fundamentals are weak: revenue fell from ~$380.8M (2023) to ~$87.4M (2024) and then to $0 in 2025 and TTM, with large net losses in 2024–TTM and deeply negative operating/free cash flow in TTM (about -$129.9M/-$130.0M). The key offset is balance-sheet strength with very low leverage and sizable equity, providing flexibility despite poor profitability.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 87.37M | 380.79M | 22.23M | 0 |
| Gross Profit | -108.00K | -525.00K | 45.22M | 355.35M | 19.24M | 0 |
| EBITDA | -160.97M | -144.16M | -290.98M | 55.38M | -197.11M | -87.88M |
| Net Income | -163.19M | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
Balance Sheet | ||||||
| Total Assets | 786.79M | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M |
| Cash, Cash Equivalents and Short-Term Investments | 768.13M | 316.98M | 176.50M | 371.36M | 346.94M | 96.12M |
| Total Debt | 4.94M | 5.96M | 1.98M | 4.24M | 6.28M | 0 |
| Total Liabilities | 33.06M | 27.39M | 28.87M | 84.02M | 50.85M | 256.78M |
| Stockholders Equity | 753.74M | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M |
Cash Flow | ||||||
| Free Cash Flow | -130.02M | -123.48M | -167.80M | 10.68M | -182.40M | -75.15M |
| Operating Cash Flow | -129.88M | -123.34M | -167.65M | 11.92M | -179.87M | -74.80M |
| Investing Cash Flow | -409.73M | 14.04M | 75.65M | 92.05M | -238.99M | -46.41M |
| Financing Cash Flow | 554.65M | 257.03M | 348.00K | 3.54M | 431.79M | 158.51M |
Amylyx Pharmaceuticals Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Neutral. The current price of 26.20 is below the 20-day moving average (MA) of 28.78, below the 50-day MA of 29.28, and above the 200-day MA of 20.99, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 40.87 is Neutral, neither overbought nor oversold. The STOCH value of 10.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMLX.
Amylyx Pharmaceuticals Inc Risk Analysis
Amylyx Pharmaceuticals Inc disclosed 91 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksAmylyx Pharmaceuticals Inc Peers Comparison
Overall Rating
HRMY77Outperform
BHVN59Neutral
AMLX54Neutral
BCRX49Neutral
DNTH45Neutral
PHVS41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $1.94B | 10.75 | 18.55% | ― | 19.79% | -4.89% | |
| 59Neutral | $1.95B | -3.34 | -2271.87% | ― | ― | 49.16% | |
| 54Neutral | $3.42B | -18.75 | -41.54% | ― | ― | 19.61% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.93B | -5.41 | 94.36% | ― | 60.30% | -3028.57% | |
| 45Neutral | $4.73B | 2799.33 | -3.87% | ― | -11.70% | -14.33% | |
| 41Neutral | $2.23B | -10.38 | -67.76% | ― | ― | 2.74% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | 26.20 | 11.53 | 78.60% | |
| BCRX | BioCryst Pharmaceuticals | 7.32 | 0.35 | 5.02% | |
| DNTH | Dianthus Therapeutics, Inc. | 84.83 | 43.38 | 104.66% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 32.98 | -1.33 | -3.88% | |
| PHVS | Pharvaris N.V. | 31.66 | 6.83 | 27.51% | |
| BHVN | Biohaven Ltd. | 13.65 | 3.96 | 40.87% |
Amylyx Pharmaceuticals Inc Corporate Events
Amylyx inks long-term manufacturing deal for avexitide
PositiveOn September 8, 2026, Amylyx Pharmaceuticals entered into a long‑term manufacturing and supply agreement with Bachem Americas, and on September 1, 2026, it signed a term sheet with Polypeptide Group AG to secure commercial‑scale production of avexiti...
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide
PositiveOn August 19, 2026, Amylyx Pharmaceuticals Inc. entered into an underwriting agreement with a syndicate of banks to issue and sell 14,090,000 shares of common stock at $35.50 per share, with an additional 2,113,500 shares available under a 30-day opt...
Amylyx Highlights Positive Phase 3 Avexitide LUCIDITY Results
PositiveOn August 18, 2026, Amylyx Pharmaceuticals hosted a conference call with investors and analysts to present positive topline data from its Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. The m...
Amylyx announces positive Phase 3 LUCIDITY avexitide results
PositiveOn August 18, 2026, Amylyx reported positive topline Phase 3 results from its LUCIDITY trial of avexitide in post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. The 78-patient study met its FDA-agreed primary endpoint, showing a 55% r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
